Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0149521 (
chronic pancreatitis
)
7,199
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The concentration of beta2-microglobulin (beta2m) and
carcinoembryonic antigen
(
CEA
) was measured radioimmunologically in the sera of 79 patients with malignant disorders and 15 patients with
chronic pancreatitis
. Elevated levels of beta2m and
CEA
were found in 11 out of 22 patients with carcinoma of the pancreas, which sets off this malignancy from
chronic pancreatitis
and other malignant tumors. Only 3 patients with carcinoma of the pancreas exhibited serum levels within the normal range for both parameters and none of the patients with
chronic pancreatitis
was shown to have elevated levels of beta2m. The simultaneous determination of beta2m and
CEA
suggests itself for the diagnosis of pancreatic malignancy especially in the case of a tentative diagnosis of a pancreatic tumor.
...
PMID:[The significance of beta2-microglobulin and carcinoembryonic antigen in the diagnosis of the carcinoma of the pancreas (author's transl)]. 7 94
We studied serum
carcinoembryonic antigen
(
CEA
) levels in 82 patients. Thirty-four of these had benign diseases while 48 had malignant diseases. Highest incidence and levels of
CEA
occurred in the sera of patients with pancreatic cancer and stomach cancer. In this paper we focused our particular attention on the serum
CEA
of 25 pancreatic cancer patients, and examined differences in serum
CEA
levels in relation to histologic differentiation and sites of pancreatric cancer. No statistical difference in serum
CEA
level was found among various histologic types and sites of the pancreatic cancer. Clinical courses of two patients with pancreatic cancer were also studied. Serial determinations of
CEA
levels are most useful in assessing the effect of operation or chemotherapies and are a useful indicator for differentiating pancreatic cancer from
chronic pancreatitis
but cannot be a conclusive factor for the diagnosis. Finally, we correlated serum
CEA
levels with those of RNase and confirmed a positive correlation.
...
PMID:Clinical studies on carcinoembryonic antigen in pancreatic cancer. 22 3
Eighty-five of 186 patients investigated for suspected pancreatic cancer had an unequivocal final diagnosis of either pancreatic cancer (58 patients) or
chronic pancreatitis
(27 patients). They had been studied prospectively using ultrasonography, computerized tomography, radionuclide scanning, endoscopic retrograde cholangiopancreatography (ERCP), selective celiac and superior mesenteric angiography, duodenal drainage studies, cytologic studies, serum
carcinoembryonic antigen
assay, and pancreatic oncofetal antigen assay, The results were compared to determine which test would most frequently and reliably differentiate between pancreatic cancer and pancreatitis in a patient believed to have one or other disease. Criteria for interpreting results, first for highest rate of correct diagnoses, and second for highest accuracy were derived. Applying these criteria, ultrasonography achieved the highest rate of correct diagnoses (97% of patients diagnosed with 84% accuracy). ERCP, duodenal drainage studies, and cytology were the most accurate tests ((86% accuracy each test) but, with this accuracy, ERCP most frequently gave a diagnosis (diagnosis rate: ERCP--70%, duodenal drainage--32%, cytology--35%). The results suggest that ultrasonography is the best noninvasive test, and that a combination of ERCP, pancreatic juice assay and cytology in a single procedure may prove to be the best discriminating investigation.
...
PMID:Non-operative differentiation between pancreatic cancer and chronic pancreatitis. 44 2
In order to test the effectiveness of CA19-9, KM01, unabsorbed CEA (
carcinoembryonic antigen
) and absorbed CEA by immunoperoxidase staining, we evaluated the staining distribution, intensity, and cellular localization in pancreatic cancer. The results were then compared with those of normal pancreas and
chronic pancreatitis
. The positive staining rate of the pancreatic cancer with any of the four tumor markers was higher than that of the normal pancreas. However, all markers except absorbed CEA showed a higher positive staining rate for
chronic pancreatitis
than for pancreatic cancer. There was no stromal type in normal pancreatic or
chronic pancreatitis
tissues with any of the four tumor markers. Our findings, therefore, indicate that absorbed CEA is useful in differentiating pancreatic cancer from normal pancreatic tissues. It is not useful in distinguishing
chronic pancreatitis
, however, unless a specific staining pattern is observed.
...
PMID:Immunohistochemical staining of pancreatic cancer with CA19-9, KM01, unabsorbed CEA, and absorbed CEA. A comparison with normal pancreas and chronic pancreatitis. 168 41
This study was performed in order to evaluate the role of various local and systemic alterations in influencing serum glycoproteic markers in patients with pancreatic cancer, and in healthy and diseased controls. Cancer antigen 19-9 (CA 19-9),
carcinoembryonic antigen
(
CEA
), and ferritin were determined in the sera of 23 control subjects, 30 patients with pancreatic cancer, 27 with
chronic pancreatitis
, and 27 with extra-pancreatic diseases mainly of gastrointestinal origin. A number of acute-phase proteins and indices of liver function and cholestasis were also assayed. The three antigens increased only in patients with pancreatic cancer. Higher CA 19-9 and
CEA
, but not ferritin, levels were found only in patients with hepatic metastases. Acute-phase proteins and synthetic functional indices were found to be higher and lower, respectively, in patients with pancreatic malignancy when compared with controls. Multiple regression analysis documented the dependence of circulating ferritin, but not of CA 19-9 and
CEA
, on the systemic indices. Canonical correlation showed a similar trend for CA 19-9 and
CEA
, which differed from that of ferritin. Ferritin was found to depend on the presence of systemic and hepatic alterations, especially of cholestasis. We can conclude that the variations of serum glycoprotein markers in patients with pancreatic cancer depend on various regional and systemic factors. CA 19-9 and
CEA
are related mainly to the extent of the neoplasia. The influence of a decreased liver function capacity associated or not to cholestasis and the interrelation with the acute-phase response may also be suggested. Ferritin, on the other hand, is related to a higher degree than CA 19-9 and
CEA
to hepatic dysfunction and also behaves similar to an acute-phase protein.
...
PMID:Role of local and systemic factors in increasing serum glycoprotein markers of pancreatic cancer. 177 Mar 22
A patient with a transient elevation of the serum
carcinoembryonic antigen
(
CEA
) associated with a benign disease was reported. The elevation of
CEA
was noted in the patient with low T3, T4 syndrome associated with malnutrition due to malabsorption syndrome induced by post-gastrectomy and
chronic pancreatitis
. Mild liver dysfunction and diabetes mellitus were also noted. The
CEA
level decreased as T3, T4 level and malnutrition were improved by administration of a massive digestive enzyme preparation. This inverse correlation between the serum
CEA
and serum T3, T4 levels suggested that high levels of the serum
CEA
can be found in the patient with malnutrition.
...
PMID:A case of transient elevation of the serum carcinoembryonic antigen and associated with severe malnutrition and low T3, T4 syndrome. 188 26
When pancreatography shows a stenosis of the main pancreatic duct in patients with normal or inconclusive ultrasound and computed tomography, the exact nature of such stenosis is sometimes difficult to precise before surgical exploration. In such cases, the authors systematically performed a percutaneous fine-needle aspiration cytologic study of the stenosis under pancreatographic guidance. Fifteen patients were referred because of suspected pancreatic malignancy. The tumor markers,
carcinoembryonic antigen
(
CEA
) and CA 19-9 were normal in 11 patients and elevated in one patient, whereas only CA 19-9 was elevated in three others. In 14 cases, both the ultrasound and computed tomography did not show any obvious pancreatic mass. The pancreatography was done through endoscopic retrograde cholangiopancreatography (ERCP) (12 patients) or percutaneously in case of failure at ERCP3 and showed a main pancreatic duct stenosis that underwent aspiration by percutaneous fine needle precisely positioned using biplane fluoroscopy. The aspirated material was then smeared on glass slides, air-dried, and stained by Giemsa. In nine of the 15 patients, cytologic study revealed adenocarcinoma. This was confirmed by surgery in five and by progressive deterioration followed by death in four. In six patients, cytologic study gave a nonmalignant result.
Chronic pancreatitis
was found in five of them, confirmed at surgery in three and based on uneventful follow-up of at least 12 months in two others. In one case, a pancreatic adenocarcinoma not detected by cytologic study was found at surgery. Thus, the sensitivity and specificity of this diagnostic approach were 90% and 100%, respectively. No serious complication was noticed. The authors conclude that when ultrasound and computed tomography are inconclusive, percutaneous fine-needle aspiration cytologic study of main pancreatic duct stenosis under pancreatographic guidance is a safe, simple, and helpful procedure in the investigation of patients with suspected pancreatic malignancy.
...
PMID:Percutaneous fine-needle aspiration cytologic study of main pancreatic duct stenosis under pancreatographic guidance. 201 42
For evaluating the diagnostic rate of serum CA19-9 and
carcinoembryonic antigen
(
CEA
) in pancreatic malignancies and pancreatitis, 22 patients with pancreatic malignancy, 27 patients with acute pancreatitis and 7 patients with
chronic pancreatitis
were included in this prospective study. The normal values of
CEA
and CA19-9 were 2.0 ng/ml and 36 U/ml respectively in 10 healthy males and 11 healthy females. The positive rates of
CEA
(greater than 2.5 ng/ml) in pancreatic malignancy, acute pancreatitis and
chronic pancreatitis
were 50%, 47% and 38%, respectively. On the other hand, the positive rates of CA19-9 (greater than 37U/ml) in pancreatic malignancy, acute pancreatitis and
chronic pancreatitis
were 82%, 26% and 23%, respectively. In diagnosis of pancreatic malignancy, the positive rate of CA19-9 is higher than that of
CEA
(82% vs 50%), and CA19-9 has a sensitivity significantly higher in differentiating from pancreatitis than
CEA
. In 7 cases of pancreatic malignancy with metastasis (liver or peritoneum), all had abnormally high serum CA19-9 (greater than 195 U/ml), 6 of 7 had CA19-9 levels over 1000 U/ml. In the view of
CEA
, 6 of 7 had serum
CEA
over 5 ng/ml, one patient with peritoneal metastasis had normal
CEA
level. In this study, we conclude that the diagnostic rate of CA19-9 in pancreatic malignancies is better than that of
CEA
.
...
PMID:[Serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA 19-9) values in patients with pancreatic cancer or pancreatitis]. 203 68
The normal pancreas consists of three major cell types or lineages that share a common embryologic origin from pluripotent endodermal precursors. The type of cell that undergoes neoplastic transformation to form a pancreatic carcinoma is controversial and may influence the phenotype and biologic behavior of the tumor. In this study, immunohistologic techniques were used to determine the cell lineage differentiation expressed in 29 primary exocrine pancreatic adenocarcinomas, five metastatic exocrine pancreatic adenocarcinomas, and five islet cell neoplasma. Specimens of normal pancreas and
chronic pancreatitis
were used for comparison. The cell lineage markers consisted of monoclonal and polyclonal antibodies against trypsin and lipase (acinar cells); secretory component, carbonic anhydrase II, and pancreatic cancer mucin SPan-1 (ductal cells); and chromogranin-A and somatostatin (islet cells). The expression of
carcinoembryonic antigen
(
CEA
) and lysozyme were also determined. This collection of markers allowed the differentiation between acinar, ductal, and islet cells of normal pancreas and
chronic pancreatitis
specimens. The expression of cell lineage markers in islet cell tumors was homogeneous and restricted to chromogranin-A. In contrast, the expression of these markers in primary and metastatic exocrine pancreatic adenocarcinomas was variable. Reactivity with monoclonal anti-
CEA
was absent in normal pancreas, and was present in 83% of
chronic pancreatitis
specimens as well as 90% of exocrine pancreatic adenocarcinomas. In addition, lysozyme reactivity was absent in normal pancreas; however, lysozyme was expressed in one case of
chronic pancreatitis
, 17 cases of primary carcinoma, and three cases of metastatic carcinoma. These findings support the concept that the original transformed cell type in many pancreatic exocrine carcinomas resemble endodermal "stem cells" that retain the capability of differentiation along more than one cell lineage pathway.
...
PMID:Cell lineage markers in human pancreatic cancer. 222 68
Comparative studies of pancreatic enzymes carbohydrate antigen 19-9 (CA 19-9) and
carcinoembryonic antigen
(
CEA
) were performed in various pancreatic disease. In acute pancreatitis as well as during acute exacerbation of
chronic pancreatitis
, all pancreatic enzymes were abnormally high. In
chronic pancreatitis
, they did not have any diagnostic sensitivity for pancreatic insufficiency. In pancreatic carcinoma, serum elastase levels may have a diagnostic value compared with other pancreatic enzymes. In studies of
CEA
and CA 19-9, both tumor markers were within normal range in benign pancreatitis but 27.7% of
CEA
and 30.7% of CA 19-9 in acute pancreatitis were above normal. In pancreatic carcinoma, although most of these patients had advanced disease, both tumor markers were extremely high and 61% for
CEA
and 71% for CA 19-9 were above normal. In patients with resected pancreatic carcinoma, serum
CEA
was slightly higher than normal CA 19-9 was much higher than normal. The sensitivity of
CEA
and CA 19-9 in this group were 33 and 77.7%, respectively. The results indicate that the CA 19-9 assay is a useful adjunct in the diagnosis of pancreatic carcinoma, possibly in the resectable stage especially combined measurement of serum elastase and
CEA
.
...
PMID:Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases. 241 Nov 25
1
2
3
4
5
Next >>